Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Côte d'Ivoire, West Africa

J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):267-73. doi: 10.1097/00126334-200311010-00002.

Abstract

The aim of this study was to evaluate the heat-dissociated p24 antigen (HD p24 Ag) assay as an alternative low-cost tool for diagnosis of HIV-1 infection and quantitation of HIV-1 RNA levels in African adults mainly infected with HIV-1 CRF02_AG strains. One hundred seventeen plasma specimens were obtained from HIV-1-seropositive subjects enrolled in the ANRS 1220 PRIMO-CI cohort (Abidjan, Côte d'Ivoire, West Africa). Results of the HD p24 Ag assay were comparable with those of HIV-1 RNA levels quantified in the same antibody-positive plasma samples by the Amplicor HIV-1 Monitor assay (1.5 version; Roche Diagnostics, Indianapolis, IN): sensitivity, 95.7% versus 96.6%, respectively; specificity (evaluated with samples from 75 seronegative subjects), 94.7% versus 100%, respectively. HD p24 Ag and HIV-1 RNA assays were weakly correlated (Spearman coefficient correlation, r = 0.33; P < 0.001) except for HIV-1 RNA levels of >/=5 log10 copies/mL (r = 0.62; P < 0.001). Quantitation of HD p24 antigenemia in 76 plasma specimens from 14 patients treated with highly active antiretroviral therapy demonstrated weaker changes during treatment than those observed with the HIV-1 RNA assay. Follow-up of infected patients using both markers showed different results. The reliability of the HD p24 Ag assay is questionable for clinical and biologic management as a surrogate tool for measurement of HIV-1 RNA levels in Africa.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Cote d'Ivoire
  • Drug Combinations
  • Enzyme-Linked Immunosorbent Assay / veterinary
  • HIV Antibodies / blood
  • HIV Core Protein p24*
  • HIV Infections / blood
  • HIV Infections / diagnosis*
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV-1 / genetics
  • HIV-1 / isolation & purification*
  • Humans
  • Indinavir / therapeutic use
  • Lamivudine / therapeutic use
  • Middle Aged
  • Prospective Studies
  • RNA, Viral / blood
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • Drug Combinations
  • HIV Antibodies
  • HIV Core Protein p24
  • RNA, Viral
  • lamivudine, zidovudine drug combination
  • Lamivudine
  • Zidovudine
  • Indinavir